Although activating mutations of BRAF (BRAFV600E) are found only in a small proportion of colon cancers, this poses a great challenge in the quest for a better outcome of the patients, in that BRAF mutations, like mutations in KRAS, are associated with resistance of colon cancer to conventional chemotherapeutic drugs and agents targeting the epidermal growth factor receptor (EGFR) [4–6]. The gene discussed is KRAS; the disease is malignant colon neoplasm.